VACCITECH (SP.ADR)/1 (2AB) - Total Liabilities

Latest as of March 2026: €25.66 Million EUR ≈ $30.01 Million USD

Based on the latest financial reports, VACCITECH (SP.ADR)/1 (2AB) has total liabilities worth €25.66 Million EUR (≈ $30.01 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 2AB net asset momentum to track the company's year-over-year net asset growth rate.

VACCITECH (SP.ADR)/1 - Total Liabilities Trend (2021–2025)

This chart illustrates how VACCITECH (SP.ADR)/1's total liabilities have evolved over time, based on quarterly financial data. See VACCITECH (SP.ADR)/1 free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

VACCITECH (SP.ADR)/1 Competitors by Total Liabilities

The table below lists competitors of VACCITECH (SP.ADR)/1 ranked by their total liabilities.

Company Country Total Liabilities
Control Bionics Ltd
AU:CBL
Australia AU$2.20 Million
Pure Hydrogen Corporation Ltd
AU:PH2
Australia AU$10.49 Million
Pergamon Status Dis Ticaret AS
IS:PSDTC
Turkey TL4.93 Billion
Woojin I&S Co Ltd
KO:010400
Korea ₩25.51 Billion
DRC Systems India Limited
NSE:DRCSYSTEMS
India Rs406.32 Million
Next Entertainment World Co. Ltd
KQ:160550
Korea ₩116.80 Billion
FNC Entertainment Co Ltd
KQ:173940
Korea ₩93.22 Billion
O.C.C. Public Company Limited
BK:OCC
Thailand ฿178.47 Million

Liability Composition Analysis (2021–2025)

This chart breaks down VACCITECH (SP.ADR)/1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VACCITECH (SP.ADR)/1 market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 6.05 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.39 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.28 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how VACCITECH (SP.ADR)/1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for VACCITECH (SP.ADR)/1 (2021–2025)

The table below shows the annual total liabilities of VACCITECH (SP.ADR)/1 from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 €23.88 Million
≈ $27.91 Million
-20.92%
2024-12-31 €30.19 Million
≈ $35.30 Million
+9.75%
2023-12-31 €27.51 Million
≈ $32.16 Million
+1.88%
2022-12-31 €27.00 Million
≈ $31.57 Million
-4.08%
2021-12-31 €28.15 Million
≈ $32.91 Million
--

About VACCITECH (SP.ADR)/1

F:2AB Germany Biotechnology
Market Cap
$24.11 Million
€20.62 Million EUR
Market Cap Rank
#24977 Global
#2156 in Germany
Share Price
€0.51
Change (1 day)
+5.65%
52-Week Range
€0.45 - €1.54
All Time High
€14.00
About

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more